CN today reported its financial and operating results for the fourth quarter and year ended December 31, 2024. "Thanks to our team and the strength of our operating model, we were able ...
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...
Expensify stock is rated a sell due to high market growth expectations, significant seat churn, minimal revenue growth, and intense competition. Read more here.